



ASX Release

21 December 2022

Acrux and Padagis announce the launch of prilocaine and lidocaine cream in the United States

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux and its partner Padagis today announced the launch of an AB-rated generic version of Emla[®] Cream in the United States.

Emla[®] (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on:

- normal intact skin for local analgesia
- genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia

Annual market sales for prilocaine 2.5% and lidocaine 2.5% cream products for the 12 months ending October 2022 were approximately \$39 million as measured by IQVIA.

CEO and Managing Director of Acrux, Michael Kotsanis, said *“This is another product from the Acrux pipeline that is being commercialised. We are pleased to partner with Padagis to launch this high volume product in the United States. Padagis is one of the leading generic companies in the United States and we are excited to work with them on a second product.”*

Padagis President and Chief Executive Officer, Sharon Kochan, stated *“At a time when other organizations are ceasing investment into generic products, this launch demonstrates our commitment to bringing, high quality, specialized, affordable products to patients and customers nationwide. The Padagis team values the collaboration with Acrux and leveraged Acrux’s development expertise and our commercial platform and leadership in the topical space with the overall result of delivering this important product to the market.”*

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit www.acrux.com.au

About Padagis

Padagis is dedicated to improving the well-being of patients and consumers by providing high quality, affordable specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide. For further information on Padagis, visit www.padagis.com



Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

Colter VanStedum

Padagis

EVP & Chief Growth Officer

E: colter.vanstedum@padagis.com